avutometinib,everolimus
verastem
['sclc', 'vs-6766', 'everolimus', 'nsclc']
the highly intermittent combination regimen of vs-6766+eeverolimus shows responses in multiple cancers and 6 month pfs in kras (non g12c) mutated nsclc. early data, more to come in these areas of unmet need. #asco22 
Passionate about Molecular Cancer Pharmacology and the need to think out of the box.